Alector, Inc. balance sheet
At the end of fiscal 2025, Alector, Inc. had total assets of $293m, total liabilities of $263m and shareholders' equity of $30.6m. It held $65.8m in cash against $10.4m of debt: net cash of $55.4m.
Balance sheet
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 32 | 65 | 90 | 50 | 329 | 154 | 75 | 33 | 66 | 60 |
| Total current assets | — | 293 | 357 | 422 | 750 | 726 | 566 | 425 | 266 | 180 |
| Total assets | — | 308 | 422 | 488 | 815 | 788 | 622 | 468 | 293 | 203 |
| Accounts payable | — | 0 | 0 | 3 | 5 | 4 | 4 | 2 | 2 | 2 |
| Deferred revenue (current) | — | 35 | 30 | 24 | 91 | 48 | 83 | 24 | 7 | 0 |
| Total current liabilities | — | 48 | 62 | 68 | 140 | 94 | 178 | 125 | 70 | 34 |
| Short-term debt | — | — | — | — | — | — | — | 0 | 0 | 10 |
| Long-term debt | — | — | — | — | — | — | 0 | 9 | 9 | 0 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 10 | 10 |
| Total liabilities | — | 195 | 227 | 221 | 514 | 573 | 488 | 342 | 263 | 213 |
| Shareholders' equity | −52 | −97 | 195 | 268 | 301 | 214 | 134 | 127 | 31 | −10 |
| Non-controlling interests and other (assets − liabilities − equity) | — | 211 | — | — | — | — | — | — | — | — |
| Net debt (negative = net cash) | −32 | −65 | −90 | −50 | −329 | −154 | −75 | −23 | −55 | −50 |
| Shares outstanding | — | 14m | 69m | 79m | 82m | 83m | 85m | 99m | 110m | 112m |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 469 | 425 | 367 | 319 | 300 | 266 | 215 | 180 |
| Total assets | 516 | 468 | 408 | 356 | 335 | 293 | 240 | 203 |
| Accounts payable | 5 | 2 | 2 | 2 | 5 | 2 | 1 | 2 |
| Deferred revenue (current) | 55 | 24 | 22 | 13 | 12 | 7 | 7 | 0 |
| Total current liabilities | 143 | 125 | 110 | 84 | 80 | 70 | 41 | 34 |
| Short-term debt | — | 0 | — | — | — | 0 | 1 | 10 |
| Long-term debt | — | 9 | 9 | 10 | 10 | 9 | 8 | 0 |
| Total debt | — | 9 | 9 | 10 | 10 | 10 | 10 | 10 |
| Total liabilities | 397 | 342 | 314 | 285 | 278 | 263 | 230 | 213 |
| Shareholders' equity | 119 | 127 | 95 | 71 | 58 | 31 | 10 | −10 |
| Shares outstanding | 98m | 99m | 100m | 101m | 107m | 110m | 111m | 112m |
Compare with peers
- Lineage Cell Therapeutics, Inc. balance sheet
- Keros Therapeutics, Inc. balance sheet
- Surrozen, Inc. balance sheet
- Mindwalk Holdings Corp. balance sheet
- Proqr Therapeutics N.V. balance sheet
Head to head: ALEC vs LCTXALEC vs KROSALEC vs SRZN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies